Please join us in welcoming Steven Chan as Attovia’s Chief Financial Officer! As CFO, Steve brings over 30 years of global finance and operations experience across #biotechnology, #healthcare, #technology, and beyond. His extensive knowledge and skillset will be integral as we enter the clinic and advance our mission to shape the future of #immunology and #inflammation. Learn more: https://lnkd.in/g-ez_6BK
Attovia Therapeutics
Biotechnology Research
Fremont, California 2,931 followers
Creating medicines for immune-mediated disease based on Attobody®, a novel biparatopic nanobody platform.
About us
Attovia is creating a pipeline of biotherapeutics with an initial focus on immune-mediated disease and oncology. We leverage ATTOBODY, a novel biologics platform, to generate small format biparatopic binders that unlock the spatial aspect of target engagement. The biparatopic binding mode of ATTOBODIES translates to picomolar affinity with glue-like off-rates, exquisite specificity, and accelerated target internalization. Their small format and modularity offer fast tissue penetration, ease of engineering into bispecifics, and tunable half-life from hours to weeks. Collectively, these properties of ATTOBODIES expand the addressable target and epitope universe across disease areas and can offer stronger efficacy, faster speed to response, and an improved safety profile compared to traditional approaches. By utilizing our ATTOBODY technology, we will develop novel medicines that target unaddressed elements of disease, as well as offer better efficacy and tolerability. We envision a world where no patient is left behind.
- Website
-
https://www.attovia.com/
External link for Attovia Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- Fremont, California
- Type
- Privately Held
- Founded
- 2023
Locations
-
Primary
Get directions
47071 Bayside Pkwy
Suite 100
Fremont, California 94538, US
Employees at Attovia Therapeutics
Updates
-
We are thrilled to announce Attovia’s newest Board members: Mitchell Gold M.D., Chairman and CEO at Alpine Immune Sciences (acquired by Vertex), and Angie You, CEO at Architect Therapeutics! Their expertise and perspective will be invaluable to the continued growth and development of Attovia as a leading I&I company. See the full announcement here: https://bit.ly/4bxAjOZ
-
-
We are excited to announce our $105M Series B funding! We're deeply grateful to both our new and existing investors for their commitment to transforming medicine through the ATTOBODY technology. We are also proud of our team at Attovia, whose dedication and innovation were instrumental to reaching this milestone. With this support, we're optimally equipped to advance our programs into the clinic. Learn more here: https://bit.ly/3URSn19 #ATTOBODY #Attovia #Immunology #SeriesB
-
-
We are excited to welcome Hubert Chen to Attovia's executive leadership team as Chief Medical Officer, effective March 21st! In his role, Dr. Chen will lead the oversight and development of Attovia’s lead programs towards the clinic. In addition, we announced the appointment of new members to our Clinical and Scientific Advisory Boards. Their extensive experience and diverse perspectives, combined with their deep passion for helping patients, will be invaluable as we continue to grow. Read more below! https://lnkd.in/g4WRXhty
-
We are thrilled to announce the second tranche closing of Attovia's $60M Series A, which was led by Frazier Healthcare Partners, with participation from venBio and Illumina Ventures! Attovia has made immense progress in building a pipeline of strong programs leveraging the proprietary Attobody™ biologics platform, with an initial focus on treating immune-mediated diseases with our anti-IL31 ATTO-1310 and bispecific anti-IL31 x IL13 ATTO-002. We are hiring across multiple roles in discovery, translational biology, and more. Join our team to help build a world where no patient is left behind! #Attobody #Bispecific #Atopicdermatitis #IL31 #Immune
Attovia Announces Second Tranche Closing of $60 Million Series A Financing and Highlights Progress Building a Best-in-Class Pipeline Leveraging the Attobody™ Platform
globenewswire.com